hims fda - Search News

Hims Stock Crashes

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.

Reuters · 15h

Hims & Hers warns it may stop selling compounded weight-loss drugs

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

Investor's Business Daily on MSN · 3d

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss and diabetes drugs has been resolved. The FDA website indicated that the shortage of Novo Nordisk's Ozempic and Wegovy has ended.

3don MSN

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...

23h

Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...

Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Hims & Hers price target raised to $61 from $31 at Needham

Needham raised the firm’s price target on Hims & Hers to $61 from $31 and keeps a Buy rating on the shares. The company reported strong Q4 ...

Modern Healthcare15h

Hims & Hers pivots as semaglutide shortage ends

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

MedCity News1d

Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?

Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...

22m

Q4 2024 Hims & Hers Health Inc Earnings Call

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...

Hims & Hers shares drop on doubts over weight-loss business forecast

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight ...

Hosted on MSN16h

IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results